source
- AstraZeneca’s GLP-1 obesity pill shows 10.5% average weight loss after six months in Phase 2 trialAstraZeneca reported data from its Phase 2 study of a GLP-1 based oral obesity treatment. The trial showed participants lost an average of 10.5% of body weight after six months of therapy. The re…
- AstraZeneca’s oral GLP-1 candidate elecoglipron cuts weight 11% in Phase 2 obesity trialA Phase 2 study (VISTA) of AstraZeneca’s oral GLP‑1 molecule elecoglipron in people with obesity showed an average weight loss of 11.2 % after 36 weeks, according to data presented at the American…